No advantage in screening for endometrial cancerBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7268.1039/a (Published 28 October 2000) Cite this as: BMJ 2000;321:1039
- Scott Gottlieb
- New York
No advantage exists in routine endometrial screening for patients with breast cancer who are being treated with tamoxifen, according to two new studies.
Although tamoxifen cuts the risk of breast cancer in some women, it also raises the risk of endometrial cancer. As a result, patients taking the drug often undergo invasive and somewhat painful biopsies and ultrasound examination of the uterine lining.
The new studies report that these commonly used screening methods are no more effective at diagnosing early endometrial cancer in these patients than watching for abnormal vaginal bleeding. Researchers found that with high rates of false positive results, the …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.